Inventory of Novel Animal Models Addressing Etiology of Preeclampsia in the Development of New Therapeutic/Intervention Opportunities

American Journal of Reproductive Immunology

Volumn 75, Issue 3, 2016, Pages 402-410

  Erlandsson, Lena ^a   Nääv, Åsa ^a   Hennessy, Annemarie ^b   Vaiman, Daniel ^c   Gram, Magnus ^a   Åkerström, Bo ^a   Hansson, Stefan R ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c INSTITUT COCHIN   (France)

Author keywords

Hypertension; placenta; proteinuria; treatment opportunities; two stage model; 1 microglobulin

Indexed keywords

ACTIVIN A; HEMOGLOBIN F;

ANIMAL EXPERIMENT; ANIMAL MODEL; EXPERIMENTAL MODEL; HUMAN; NONHUMAN; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; STARVATION;

EID: 84977555077     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12460     Document Type: Review

References (90)

1. McCarthy FP, Kingdom JC, Kenny LC, Walsh SK: Animal models of preeclampsia; uses and limitations. Placenta 2011; 32:413–419.
2. Roberts JM, Cooper DW: Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357:53–56.
3. Roberts JM, Hubel CA: The two stage model of preeclampsia: variations on the theme. Placenta 2009; 30(Suppl A):S32–S37.
4. Brosens JJ, Pijnenborg R, Brosens IA: The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am J Obstet Gynecol 2002; 187:1416–1423.
5. Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ: Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. Circ Res 2002; 90:1274–1281.
6. Lipstein H, Lee CC, Crupi RS: A current concept of eclampsia. Am J Emerg Med 2003; 21:223–226.
7. Stillman IE, Karumanchi SA: The glomerular injury of preeclampsia. J Am Soc Nephrol 2007; 18:2281–2284.
8. Roberts JM: Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16:5–15.
9. Carter AM, Pijnenborg R: Evolution of invasive placentation with special reference to non-human primates. Best Pract Res Clin Obstet Gynaecol 2011; 25:249–257.
10. Schmidt A, Morales-Prieto DM, Pastuschek J, Frohlich K, Markert UR: Only humans have human placentas: molecular differences between mice and humans. J Reprod Immunol 2015; 108:65–71.
11. Podjarny E, Losonczy G, Baylis C: Animal models of preeclampsia. Semin Nephrol 2004; 24:596–606.
12. Sunderland N, Hennessy A, Makris A: Animal models of pre-eclampsia. Am J Reprod Immunol 2011; 65:533–541.
13. Carter AM: Animal models of human placentation–a review. Placenta 2007; 28(Suppl A):S41–S47.
14. Davisson RL, Hoffmann DS, Butz GM, Aldape G, Schlager G, Merrill DC, Sethi S, Weiss RM, Bates JN: Discovery of a spontaneous genetic mouse model of preeclampsia. Hypertension 2002; 39:337–342.
15. Dokras A, Hoffmann DS, Eastvold JS, Kienzle MF, Gruman LM, Kirby PA, Weiss RM, Davisson RL: Severe feto-placental abnormalities precede the onset of hypertension and proteinuria in a mouse model of preeclampsia. Biol Reprod 2006; 75:899–907.
16. Hoffmann DS, Weydert CJ, Lazartigues E, Kutschke WJ, Kienzle MF, Leach JE, Sharma JA, Sharma RV, Davisson RL: Chronic tempol prevents hypertension, proteinuria, and poor feto-placental outcomes in BPH/5 mouse model of preeclampsia. Hypertension 2008; 51:1058–1065.
17. Gelber SE, Brent E, Redecha P, Perino G, Tomlinson S, Davisson RL, Salmon JE: Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency. J Immunol 2015; 195:1129–1138.
18. Woods AK, Hoffmann DS, Weydert CJ, Butler SD, Zhou Y, Sharma RV, Davisson RL: Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice. Hypertension 2011; 57:94–102.
19. Gillis EE, Williams JM, Garrett MR, Mooney JN, Sasser JM: The Dahl salt-sensitive rat is a spontaneous model of superimposed preeclampsia. Am J Physiol Regul Integr Comp Physiol 2015; 309:R62–R70.
20. Sibai BM, Lindheimer M, Hauth J, Caritis S, VanDorsten P, Klebanoff M, MacPherson C, Landon M, Miodovnik M, Paul R, Meis P, Dombrowski M: Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 339:667–671.
21. Li J, LaMarca B, Reckelhoff JF: A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model. Am J Physiol Heart Circ Physiol 2012; 303:H1–H8.
22. Cavanagh D, Rao PS, Knuppel RA, Desai U, Balis JU: Pregnancy-induced hypertension: development of a model in the pregnant primate (Papio anubis). Am J Obstet Gynecol 1985; 151:987–999.
23. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A: Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007; 71:977–984.
24. Thatcher CD, Keith JC Jr: Pregnancy-induced hypertension: development of a model in the pregnant sheep. Am J Obstet Gynecol 1986; 155:201–207.
25. Losonczy G, Brown G, Venuto RC: Increased peripheral resistance during reduced uterine perfusion pressure hypertension in pregnant rabbits. Am J Med Sci 1992; 303:233–240.
26. Golden JG, Hughes HC, Lang CM: Experimental toxemia in the pregnant guinea pig (Cavia porcellus). Lab Anim Sci 1980; 30:174–179.
27. Woods LL: Importance of prostaglandins in hypertension during reduced uteroplacental perfusion pressure. Am J Physiol 1989; 257:R1558–R1561.
28. Morton JS, Andersson IJ, Cheung PY, Baker P, Davidge ST: The vascular effects of sodium tanshinone IIA sulphonate in rodent and human pregnancy. PLoS ONE 2015; 10:e0121897.
29. Amaral LM, Cornelius DC, Harmon A, Moseley J, Martin JN Jr, LaMarca B: 17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model. Hypertension 2015; 65:225–231.
30. Ma RQ, Sun MN, Yang Z: Effects of preeclampsia-like symptoms at early gestational stage on feto-placental outcomes in a mouse model. Chin Med J (Engl) 2010; 123:707–712.
31. Molnar M, Suto T, Toth T, Hertelendy F: Prolonged blockade of nitric oxide synthesis in gravid rats produces sustained hypertension, proteinuria, thrombocytopenia, and intrauterine growth retardation. Am J Obstet Gynecol 1994; 170:1458–1466.
32. Alpoim PN, Gomes KB, Pinheiro Mde B, Godoi LC, Jardim LL, Muniz LG, Sandrim VC, Fernandes AP, Dusse LM: Polymorphisms in endothelial nitric oxide synthase gene in early and late severe preeclampsia. Nitric Oxide 2014; 42:19–23.
33. Baijnath S, Soobryan N, Mackraj I, Gathiram P, Moodley J: The optimization of a chronic nitric oxide synthase (NOS) inhibition model of pre-eclampsia by evaluating physiological changes. Eur J Obstet Gynecol Reprod Biol 2014; 182:71–75.
34. Motta C, Grosso C, Zanuzzi C, Molinero D, Picco N, Bellingeri R, Alustiza F, Barbeito C, Vivas A, Romanini MC: Effect of sildenafil on pre-eclampsia-like mouse model induced by l-Name. Reprod Domest Anim 2015; 50:611–616.
35. Ramesar SV, Mackraj I, Gathiram P, Moodley J: Sildenafil citrate improves fetal outcomes in pregnant, l-NAME treated, Sprague-Dawley rats. Eur J Obstet Gynecol Reprod Biol 2010; 149:22–26.
36. Rossoni G, Manfredi B, De Gennaro Colonna V, Berti M, Guazzi M, Berti F: Sildenafil reduces l-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Br J Pharmacol 2007; 150:567–576.
37. Ramesar SV, Mackraj I, Gathiram P, Moodley J: Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley rats. Eur J Obstet Gynecol Reprod Biol 2011; 157:136–140.
38. Nassar AH, Masrouha KZ, Itani H, Nader KA, Usta IM: Effects of sildenafil in Nomega-nitro-l-arginine methyl ester-induced intrauterine growth restriction in a rat model. Am J Perinatol 2012; 29:429–434.
39. Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, Baker PN: A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009; 28:369–382.
40. Zou Y, Zuo Q, Huang S, Yu X, Jiang Z, Zou S, Fan M, Sun L: Resveratrol inhibits trophoblast apoptosis through oxidative stress in preeclampsia-model rats. Molecules 2014; 19:20570–20579.
41. Santillan MK, Santillan DA, Scroggins SM, Min JY, Sandgren JA, Pearson NA, Leslie KK, Hunter SK, Zamba GK, Gibson-Corley KN, Grobe JL: Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model. Hypertension 2014; 64:852–859.
42. Bartha JL, Visiedo F, Fernandez-Deudero A, Bugatto F, Perdomo G: Decreased mitochondrial fatty acid oxidation in placentas from women with preeclampsia. Placenta 2012; 33:132–134.
43. Ding X, Yang Z, Han Y, Yu H: Long-chain fatty acid oxidation changes in a beta2 glycoprotein I-induced preeclampsia-like mouse model. Placenta 2014; 35:392–397.
44. Lim R, Adhikari S, Gurusinghe S, Leaw B, Acharya R, Rahman R, Ciayadi R, Potdar M, Kelso GF, Hearn MT, Wallace EM: Inhibition of activin A signalling in a mouse model of pre-eclampsia. Placenta 2015; 36:926–931.
45. Centlow M, Carninci P, Nemeth K, Mezey E, Brownstein M, Hansson SR: Placental expression profiling in preeclampsia: local overproduction of hemoglobin may drive pathological changes. Fertil Steril 2008; 90:1834–1843.
46. May K, Rosenlof L, Olsson MG, Centlow M, Morgelin M, Larsson I, Cederlund M, Rutardottir S, Siegmund W, Schneider H, Akerstrom B, Hansson SR: Perfusion of human placenta with hemoglobin introduces preeclampsia-like injuries that are prevented by alpha1-microglobulin. Placenta 2011; 32:323–332.
47. Winterbourn CC: Oxidative reactions of hemoglobin. Methods Enzymol 1990; 186:265–272.
48. Anderson UD, Olsson MG, Rutardottir S, Centlow M, Kristensen KH, Isberg PE, Thilaganathan B, Akerstrom B, Hansson SR: Fetal hemoglobin and alpha1-microglobulin as first- and early second-trimester predictive biomarkers for preeclampsia. Am J Obstet Gynecol 2011; 204:520 e521–520 e525.
49. Hansson SR, Gram M, Akerstrom B: Fetal hemoglobin in preeclampsia: a new causative factor, a tool for prediction/diagnosis and a potential target for therapy. Curr Opin Obstet Gynecol 2013; 25:448–455.
50. Hansson SR, Naav A, Erlandsson L: Oxidative stress in preeclampsia and the role of free fetal hemoglobin. Front Physiol 2014; 5:516.
51. Naav A, Erlandsson L, Axelsson J, Larsson I, Johansson M, Wester-Rosenlof L, Morgelin M, Casslen V, Gram M, Akerstrom B, Hansson SR: A1M ameliorates preeclampsia-like symptoms in placenta and kidney induced by cell-free fetal hemoglobin in rabbit. PLoS One 2015; 10:e0125499.
52. Akerstrom B, Gram M: A1M, an extravascular tissue cleaning and housekeeping protein. Free Radic Biol Med 2014; 74C:274–282.
53. Olsson MG, Allhorn M, Bulow L, Hansson SR, Ley D, Olsson ML, Schmidtchen A, Akerstrom B: Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for alpha(1)-microglobulin. Antioxid Redox Signal 2012; 17:813–846.
54. Tejler L, Eriksson S, Grubb A, Astedt B: Production of protein HC by human fetal liver explants. Biochim Biophys Acta 1978; 542:506–514.
55. DeMars DD, Katzmann JA, Kimlinger TK, Calore JD, Tracy RP: Simultaneous measurement of total and IgA-conjugated alpha 1-microglobulin by a combined immunoenzyme/immunoradiometric assay technique. Clin Chem 1989; 35:766–772.
56. Wester L, Fast J, Labuda T, Cedervall T, Wingardh K, Olofsson T, Akerstrom B: Carbohydrate groups of alpha1-microglobulin are important for secretion and tissue localization but not for immunological properties. Glycobiology 2000; 10:891–900.
57. Larsson J, Wingardh K, Berggard T, Davies JR, Logdberg L, Strand SE, Akerstrom B: Distribution of iodine 125-labeled alpha1-microglobulin in rats after intravenous injection. J Lab Clin Med 2001; 137:165–175.
58. Olsson MG, Allhorn M, Larsson J, Cederlund M, Lundqvist K, Schmidtchen A, Sorensen OE, Morgelin M, Akerstrom B: Up-regulation of A1M/alpha1-microglobulin in skin by heme and reactive oxygen species gives protection from oxidative damage. PLoS One 2011; 6:e27505.
59. Olsson MG, Nilsson EJ, Rutardottir S, Paczesny J, Pallon J, Akerstrom B: Bystander cell death and stress response is inhibited by the radical scavenger alpha(1)-microglobulin in irradiated cell cultures. Radiat Res 2010; 174:590–600.
60. Olsson MG, Olofsson T, Tapper H, Akerstrom B: The lipocalin alpha1-microglobulin protects erythroid K562 cells against oxidative damage induced by heme and reactive oxygen species. Free Radic Res 2008; 42:725–736.
61. Wester-Rosenlof L, Casslen V, Axelsson J, Edstrom-Hagerwall A, Gram M, Holmqvist M, Johansson ME, Larsson I, Ley D, Marsal K, Morgelin M, Rippe B, Rutardottir S, Shohani B, Akerstrom B, Hansson SR: A1M/alpha1-microglobulin protects from heme-induced placental and renal damage in a pregnant sheep model of preeclampsia. PLoS One 2014; 9:e86353.
62. Talosi G, Nemeth I, Nagy E, Pinter S: The pathogenetic role of heme in pregnancy-induced hypertension-like disease in ewes. Biochem Mol Med 1997; 62:58–64.
63. Hennessy A, Gillin A, Horvath J: Cardiovascular research in pregnancy – the role of animal-models. Hypertens Pregnancy 1993; 12:413–437.
64. Hennessy A, Gillin AG, Duggin GG, Horvath JS, Tiller DJ: Low-dose nitro-l-arginine administration in baboon (Papio hamadryas) pregnancy. Clin Exp Pharmacol Physiol 1999; 26:849–852.
65. Hennessy A, Gillin AG, Thompson JF, Painter DM, Waugh RD, Duggin GG, Tiller DJ, Horvath JS: Endothelin in primate pregnancy and an experimental preeclampsia-like syndrome. Hypertens Pregnancy 1998; 17:227–240.
66. Orange S, Rasko JE, Thompson JF, Vaughan J, Olive E, Pedler M, Horvath JS, Hennessy A: Interleukin-10 regulates arterial pressure in early primate pregnancy. Cytokine 2005; 29:176–185.
67. Hennessy A, Pilmore HL, Simmons LA, Painter DM: A deficiency of placental IL-10 in preeclampsia. J Immunol 1999; 163:3491–3495.
68. Sunderland NS, Thomson SE, Heffernan SJ, Lim S, Thompson J, Ogle R, McKenzie P, Kirwan PJ, Makris A, Hennessy A: Tumor necrosis factor alpha induces a model of preeclampsia in pregnant baboons (Papio hamadryas). Cytokine 2011; 56:192–199.
69. Parrish MR, Murphy SR, Rutland S, Wallace K, Wenzel K, Wallukat G, Keiser S, Ray LF, Dechend R, Martin JN, Granger JP, LaMarca B: The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble Endoglin production in response to hypertension during pregnancy. Am J Hypertens 2010; 23:911–916.
70. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y: The role of the immune system in preeclampsia. Mol Aspects Med 2007; 28:192–209.
71. Wang Y, Walsh SW: TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol 1996; 32:157–169.
72. Murphy SR, LaMarca BB, Parrish M, Cockrell K, Granger JP: Control of soluble fms-like tyrosine-1 (sFlt-1) production response to placental ischemia/hypoxia: role of tumor necrosis factor-alpha. Am J Physiol Regul Integr Comp Physiol 2013; 304:R130–R135.
73. Santillan MK, Pelham CJ, Ketsawatsomkron P, Santillan DA, Davis DR, Devor EJ, Gibson-Corley KN, Scroggins SM, Grobe JL, Yang B, Hunter SK, Sigmund CD: Pregnant mice lacking indoleamine 2,3-dioxygenase exhibit preeclampsia phenotypes. Physiol Rep 2015; 3:e12257.
74. Chatterjee P, Kopriva SE, Chiasson VL, Young KJ, Tobin RP, Newell-Rogers K, Mitchell BM: Interleukin-4 deficiency induces mild preeclampsia in mice. J Hypertens 2013; 31:1414–1423; discussion 1423.
75. Lai Z, Kalkunte S, Sharma S: A critical role of interleukin-10 in modulating hypoxia-induced preeclampsia-like disease in mice. Hypertension 2011; 57:505–514.
76. Inagaki A, Nishizawa H, Ota S, Suzuki M, Inuzuka H, Miyamura H, Sekiya T, Kurahashi H, Udagawa Y: Upregulation of HtrA4 in the placentas of patients with severe pre-eclampsia. Placenta 2012; 33:919–926.
77. Hasan MZ, Ikawati M, Tocharus J, Kawaichi M, Oka C: Abnormal development of placenta in HtrA1-deficient mice. Dev Biol 2015; 397:89–102.
78. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Brasen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Muller DN: Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension 2005; 45:742–746.
79. Przybyl L, Ibrahim T, Haase N, Golic M, Rugor J, Luft FC, Bendix I, Serdar M, Wallukat G, Staff AC, Muller DN, Hunig T, Felderhoff-Muser U, Herse F, LaMarca B, Dechend R: Regulatory T cells ameliorate intrauterine growth retardation in a transgenic rat model for preeclampsia. Hypertension 2015; 65:1298–1306.
80. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672–683.
81. Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P, Lindenmaier W, Christofori G, Gross V, Gonzalves A, Grone HJ, Ahmed A, Weich HA: Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 2010; 14:1857–1867.
82. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649–658.
83. Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, Wenger J, Lucchesi KJ, Tamez H, Lindner T, Fridman A, Thome U, Kribs A, Danner M, Hamacher S, Mallmann P, Stepan H, Benzing T: Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol 2015; 27. [Epub ahead of print].
84. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH, Mallmann P, Stepan H, Karumanchi SA, Benzing T: Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124:940–950.
85. Pruthi D, Khankin EV, Blanton RM, Aronovitz M, Burke SD, McCurley A, Karumanchi SA, Jaffe IZ: Exposure to experimental preeclampsia in mice enhances the vascular response to future injury. Hypertension 2015; 65:863–870.
86. van Dijk M, Mulders J, Poutsma A, Konst AA, Lachmeijer AM, Dekker GA, Blankenstein MA, Oudejans CB: Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. Nat Genet 2005; 37:514–519.
87. Rigourd V, Chauvet C, Chelbi ST, Rebourcet R, Mondon F, Letourneur F, Mignot TM, Barbaux S, Vaiman D: STOX1 overexpression in choriocarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas. PLoS One 2008; 3:e3905.
88. Doridot L, Passet B, Mehats C, Rigourd V, Barbaux S, Ducat A, Mondon F, Vilotte M, Castille J, Breuiller-Fouche M, Daniel N, le Provost F, Bauchet AL, Baudrie V, Hertig A, Buffat C, Simeoni U, Germain G, Vilotte JL, Vaiman D: Preeclampsia-like symptoms induced in mice by fetoplacental expression of STOX1 are reversed by aspirin treatment. Hypertension 2013; 61:662–668.
89. Doridot L, Chatre L, Ducat A, Vilotte JL, Lombes A, Mehats C, Barbaux S, Calicchio R, Ricchetti M, Vaiman D: Nitroso-redox balance and mitochondrial homeostasis are regulated by STOX1, a pre-eclampsia-associated gene. Antioxid Redox Signal 2014; 21:819–834.
90. Ducat A, Doridot L, Calicchio R, Méhats C, Vilotte JL, Castille J, Barbaux S, Couderc B, Jacques S, Letourneur F, Buffat C, Le Grand F, Laissue P, Miralles F, Vaiman D: Endothelial cell dysfunction and cardiac hypertrophy in the STOX1 model of preeclampsia. Sci Rep 2015 [Epub ahead of print].